生物制剂联合JAK抑制剂治疗难治性系统性自身炎症性疾病
完全缓解21例(55.3%)、部分缓解12例(31.6%)、无缓解5例(13.1%);末次随访26例(68%)仍在ACT,中位疗程60个月。ACT对难治性SAIDs有显著临床获益,但存在继发失效与感染风险。
要点
- ACT在难治性SAIDs中完全缓解率55.3%、部分缓解率31.6%。
- 最常用联合方案为IL-1抑制剂联合TNF抑制剂。
核心结论
- ACT可为难治性SAIDs患者带来显著临床获益,但继发失效与感染风险仍是挑战。
主要发现
- 完全缓解21例(55.3%)、部分缓解12例(31.6%)、无缓解5例(13.1%)。
- 共给予65个ACT方案,最常见为IL-1抑制剂联合TNF抑制剂。
- 末次随访26例(68%)仍在ACT,中位治疗时长60个月(范围11-186个月)。
关键数值与推荐
- ACT定义为生物制剂和/或JAK抑制剂联合使用。
- 疗效采用复合结局评估,纳入糖皮质激素剂量、C反应蛋白(CRP)及临床改善,分为无缓解、部分缓解和完全缓解。
临床怎么用
- 对常规单药治疗难治且依赖糖皮质激素和/或阿片类药物的SAIDs患者,可考虑ACT。
- ACT期间需监测继发失效与感染风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Systemic autoinflammatory diseases (SAIDs) arise from genetic defects in innate immunity, leading to dysregulated activation of inflammatory pathways, including interleukin (IL)-1, IL-6, TNF, and JAK/STAT. Clinical manifestations range from recurrent fever to severe complications such as encephalitis and AA amyloidosis. Management aims to control inflammation using immunosuppressive agents and targeted monotherapies (biologics or JAK inhibitors). Advanced combination therapy (ACT), defined as the use of biologics and/or JAK inhibitors in combination, has emerged as a strategy for refractory disease. METHODS: In this observational retrospective longitudinal cohort study, patients with SAIDs treated with ACT were included. Demographic, clinical, treatment, and safety data were collected. Treatment response was assessed using a composite outcome incorporating corticosteroid dose, C-reactive protein (CRP), and clinical improvement and categorized as non-response, partial response, or complete response. RESULTS: Thirty-eight patients (median age 30 years [range 4-76]) were included. The most common indications for ACT were pyogenic arthritis, pyoderma gangrenosum and acne (PAPA), mevalonate kinase deficiency (MKD), and undifferentiated SAIDs. Most patients had disease-related complications and were dependent on glucocorticoids and/or opioids to control inflammation and pain, respectively. Following multiple ACT trials, complete response was observed in 21 patients (55.3%), partial response in 12 (31.6%), and no response in 5 (13.1%). Overall, 65 ACT regimens were administered, most commonly combining IL-1 and TNF inhibitors. Thirty-nine regimens were discontinued because of lack of efficacy, secondary loss of response, or adverse events. At the final follow-up, 26 patients (68%) remained on ACT, with a median treatment duration of 60 months (range, 11-186). CONCLUSIONS: ACT offers significant clinical benefits for patients with difficult-to-treat SAIDs, though challenges such as secondary loss of efficacy and infection risks remain.
引用
- Tufan A, Stone DL, Romeo T, et al. Biologic-biologic and biologic-JAK inhibitor combination therapy in refractory systemic autoinflammatory diseases. Semin Arthritis Rheum. 2026. PMID: 42691741. doi:10.1016/j.semarthrit.2026.153067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。